Ku ya 26 Mutarama 2025, Ikigo gishinzwe Isuzuma ry'Imiti (CDE) cy'Ikigo cy'Igihugu cy'Ubushinwa gishinzwe Ibikoresho by'Ubuvuzi cyatangaje ko inshinge za LM-108 zigenewe gushyirwa mu buvuzi bugezweho ku bibyimba bikomeye bifite imirasire idahindagurika (MSI-H) cyangwa inenge zo gusana zidahuye (dMMR) zakomeje gutera imbere nyuma yo kuvurwa hakoreshejwe imiti igabanya ubukana bw'umubiri (ICI).
LM-108 ni antibody nshya ya Fc-optimized, anti-CCR8 monoclonal antibody igabanya mu buryo bwihariye Tregs zinjira mu tumori.
Ku bijyanye na CCR8:
CCR8 (receptor ya chemokine 8) ni imwe mu zigize umuryango wa chemokine receptor ugizwe na receptor ya G protein-coupled (GPCR). Ubushakashatsi bwakozwe mbere bwagaragaje ko CCR8 igaragara hasi mu tunyangingo tw’amaraso two mu mpande no mu tunyangingo dusanzwe, ariko cyane cyane yiyongera mu tunyangingo twinjira mu tunyangingo muri kanseri nyinshi zirimo kanseri y’ibere, kanseri y’inkondo y’umura, na kanseri y’ibihaha. Utunyangingo twa Anit-CCR8 dushobora gufasha mu buryo bwihariye kugabanuka kwa Tregs zinjira mu tunyangingo, bityo bikongera ubushobozi bwo kurwanya kanseri kandi bikabuza gukura kwa kanseri.
AInama ngarukamwaka ya ASCO 2024，Tanga raporo ku isesengura ry’ibyavuye mu bushakashatsi bwakozwe mu cyiciro cya 3 cya 1/2 (NCT05199753; NCT05255484; NCT05518045) kugira ngo usuzume imikorere n’umutekano wa LM-108 hamwe n’ubuvuzi bwo kurwanya PD-1 ku barwayi ba kanseri y’igifu.
Uburyo: Abarwayi bemewe barwaye kanseri y'igifu bavuwe na LM-108 hamwe na antibody ya anti-PD-1 bashyizwe mu isesengura. Abarwayi bahawe LM-108 mu mitsi ku gipimo cya 3 mg/kg Q2W, 6 mg/kg Q3W, cyangwa 10 mg/kg Q3W hamwe na antibody ya anti-PD-1 (impyiko ya pembrolizumab 200 mg Q3W cyangwa 400 mg Q6W cyangwa toripalimab 240 mg Q3W). Incamake y'ibanze yari ORR yasuzumwe n'umushakashatsi kuri RECIST v1.1. Incamake y'inyongera yarimo umutekano, ibindi bisubizo by'ingirakamaro, n'isesengura ry'ibipimo. Itariki ntarengwa yo gusesengura hamwe yari ku ya 25 Ukuboza 2023.
Ibisubizo: Abarwayi 48 barwaye kanseri y'igifu (imyaka iri hagati: imyaka 60.5; abagabo: 72.9%) bakomoka mu Bushinwa, muri Amerika na Ositaraliya bavuwe ≥ dose 1 ya LM-108 hamwe na pembrolizumab cyangwa toripalimab. Abenshi mu barwayi (n = 47, 97.9%) bari barahawe nibura ubuvuzi bumwe mbere bwo kurwanya kanseri, naho 43 (89.6%) bari barahawe ubuvuzi bwa anti-PD-1 mbere. Ingaruka mbi zijyanye n'ubuvuzi (TRAEs) zabaye ku barwayi 39 (81.3%), aho ingaruka zikunze kugaragara cyane (≥15%) zari iziyongereyeho alanine transaminase (25.0%), aspartate transaminase yiyongeraho (22.9%), uturemangingo tw'amaraso twagabanutseho (22.9%), amaraso make (16.7%). Impamyabumenyi y’indwara ya TRAE ya ≥ 3 yagaragaye ku barwayi 18 (37.5%), indwara ikunze kugaragara cyane (≥ 4%) ni ukubura amaraso (8.3%), kwiyongera kwa lipase (4.2%), gucika uduheri (4.2%), n’umubare wa limfositi waragabanutse (4.2%). Mu barwayi 36 bapimwe ubushobozi bwabo mu mikorere yose, ORR yari 36.1% (95% CI 20.8%–53.8%) naho DCR yari 72.2% (95% CI 54.8%–85.8%). Igipimo cya PFS cyari amezi 6.53 (95% CI 2.96–NA). Mu barwayi 11 indwara yabo yari imaze gutera ku miti ya mbere, ORR yari 63.6% (95% CI 30.8%–89.1%) naho DCR yari 81.8% (95% CI 48.2%–97.7%). Mu barwayi 11 bavuwe ku rwego rwa mbere, 8 bari bafite CCR8 nyinshi. Muri abo barwayi 8, ORR yari 87.5% naho DCR yari 100%, aho CR 1, PR 6, na SD 1 yagaragaye.
Umwanzuro: LM-108 hamwe n'umuti urwanya kanseri ya PD-1 byagaragaje ko birwanya kanseri ku barwayi ba kanseri y'igifu, ariko bikaba byari bihanganye n'imiti irwanya kanseri ya PD-1. Iyi miti yavuyemo yari yihanganiwe neza. Ibi bisubizo bishyigikira isuzuma ryinshi rya LM-108 muri kanseri y'igifu ya CCR8.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Amareferensi
1.https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d
2.https://www.lanovamedicines.com/en
3.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2504
Igihe cyo kohereza: Gashyantare-06-2025